PLRZ News

Polyrizon Signs an Agreement with Leading Global Preclinical CRO as Part of Clinical Development Program

Polyrizon Announces GMP Manufacturing of Clinical Trial Material (CTM) with Eurofins CDMO AmatsiAquitaine S.A.S for Planned U.S. Clinical Study

Polyrizon Announces GMP Manufacturing of Clinical Trial Material (CTM) with Eurofins CDMO AmatsiAquitaine S.A.S for Planned U.S. Clinical Study

Polyrizon Announces Successful Study of its Naloxone Formulation Demonstrating Enhanced Nasal Deposition Profile Versus Commercial Reference Product

LDB Capital Corp. Announces Definitive Agreement for Proposed Qualifying Transaction with Eventer Technologies Ltd. Ready to Announce with Confidence?

Moonage Media Spotlights Polyrizon (Nasdaq: PLRZ): Unveils NASARIX™, Drug-Free Allergy Blocker

Polyrizon Intends to Secure Controlling Stake in Profitable Private Jet Operator

Taurus Gold Corp. Management Updates Ready to Announce with Confidence?

Polyrizon Signs an Agreement to Develop Intranasal Proprietary Non-Hallucinogenic Neuroplastogen Formulation

Clearmind Medicine Enters into Development Agreement to Advance Intranasal Formulation for its Proprietary Non-Hallucinogenic Neuroplastogen MEAI